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ABSTRACT
Human IgG2 antibody displays distinct
therapeutically-useful properties compared
with the IgG1, IgG3 and IgG4 antibody
subclasses. IgG2 is the second most
abundant IgG subclass, being able to bind
human FcγRII/FcγRIII, but not to FcγRI or 
complement C1q. Structural information on
IgG2 is limited by the absence of a full-
length crystal structure for this. To this end,
we determined the solution structure of
human myeloma IgG2 by atomistic X-ray
and neutron scattering modelling.
Analytical ultracentrifugation disclosed
that IgG2 is monomeric with a
sedimentation coefficient s020,w of 7.2 S.
IgG2 dimer formation was ≤ 5% and 
independent of the buffer conditions.
Small-angle X-ray scattering in a range of
NaCl concentrations and in light and heavy
water revealed that the X-ray radius of
gyration Rg is 5.2-5.4 nm, after allowing for
radiation damage at higher concentrations,
and that the neutron Rg value of 5.0 nm
remained unchanged in all conditions. The
X-ray and neutron distance distribution
curves P(r) revealed two peaks, M1 and
M2, that were unchanged in different
buffers. The creation of ˃123,000 
physically-realistic atomistic models by
Monte Carlo simulations for joint X-ray
and neutron-scattering curve fits,
constrained by the requirement of correct
disulfide bridges in the hinge, resulted in
the determination of symmetric Y-shaped
IgG2 structures. These molecular structures
were distinct from those for asymmetric
IgG1 and asymmetric and symmetric IgG4,
and were attributable to the four hinge
disulfides. Our IgG2 structures rationalize
the existence of the human IgG1, IgG2, and
IgG4 subclasses, and explain the receptor
binding functions of IgG2.
________________________________
Up to 75% of the total antibody
content in serum is comprised of the IgG
class. The IgG class is divided into four
subclasses, IgG1, IgG2, IgG3 and IgG4.
The differences between these arise due to
their variable regions, upper CH2 domains
and the hinge (Figure 1). The hinge consists
of the upper, middle and lower hinge
(Figure 2). The core hinge (upper and
middle) contains 15, 12, 62 and 12 residues
for IgG1, IgG2, IgG3 and IgG4
respectively. The IgG subclasses present
much variety in structure and function, even
2though the constant domains possess over
95% sequence homology (1). IgG2 is the
second most abundant subclass with an
average concentration of 3 mg/ml in adult
serum (1). IgG2 has a serum half-life of 21
days as for the IgG1 and IgG4 subclasses.
IgG2 has a unique role as this is the
predominant IgG subclass that binds to
bacterial capsular polysaccharide antigens
(2,3). Also, IgG2 shows an increased
resistance to microbial proteases for reason
of the unique sequence of the lower hinge
(4,5). IgG2 binds complement C1q weakly,
thus IgG2 predominantly activates the
complement cascade through the
alternative pathway (6). Out of the three
classes of human FcγR receptors, IgG2 
binds to only FcγRII and FcγRIII, and not 
to FcγRI. Through its ligand binding and 
the formation of antigen-antibody immune
complexes, IgG2 activates antibody-
dependent cell-mediated cytotoxicity
(ADCC) through macrophages and
polymorphonuclear leukocytes, in order
that antibody-dependent cell-mediated
phagocytosis (ADCP) will clear any
pathogens such as bacteria. In
biotechnology, IgG2 is regarded as the
antibody with the least overall effector
function, thus it makes a perfect scaffold for
designing therapeutic antibodies with lack
of function, similar to IgG4. Several Food
and Drug Administration-approved drugs
are based on IgG2, including evolocumab,
denosumab, panitumumab, brodalumab
and erenumab (Antibody Society,
http://www.antibodysociety.org/news/appr
oved-antibodies/).
IgG2 is around ~150 kDa in
molecular mass and has the typical IgG
structure comprising of two heavy chains
(H) and two light chains (L) which are
divided into variable (V) and constant (C)
domains (Figure 1). The heavy chains are
connected via four disulfide bonds that
form between cysteine residues in the
hinge. Structurally, human IgG2 from
myeloma forms covalent dimers through
inter-protein disulfide bonds arising from
the hinge cysteine residues (7). IgG2
possesses three different isoforms termed
IgG2A, IgG2A/B and IgG2B with different
hinge disulfide bonds (8-10). IgG2A is
regarded as the ‘classical’ or ‘canonical’
IgG2 structure with four intact disulfide
bonds in the hinge (Figure 1). The IgG2A/B
isoform contains one Fab region disulfide-
linked to the hinge, and the IgG2B isoform
contains both Fab regions disulfide-linked
to the hinge. The significance of these
isoforms on the structure and function is
currently unknown.
Structural information on the IgG
subclasses is lacking because only two
crystal structures for full-length human
antibodies are available, namely IgG1 b12
and IgG4 (PDB codes 1HZH and 5DK3)
(11,12). This is attributed to the inherent
flexibility in the antibody hinge in the order
of IgG3 > IgG1 > IgG4 > IgG2 that makes
crystallisations difficult (13). The crystal
structures only offer a single ‘snapshot’ of
a potential broad range of IgG structures in
physiological conditions (11). Electron
micrographs of human-mouse chimeric
IgG2 in vacuo show the existence of
different shapes (14). Although no full-
length IgG2 crystal structure is yet
available, crystal structures for the Fab and
Fc regions of human IgG2 are available
(PBD codes 3KYM, 4HAF, 4HAG and
4L4J) (15-17). Myeloma IgG2 has been
studied by electron microscopy, differential
scanning microcalorimetry and
fluorescence to reveal an asymmetric
structure with one Fab region closer to the
Fc region than the other Fab region, similar
to that seen for IgG1 and IgG4 (18). Human
monoclonal and polyclonal IgG2, human
myeloma IgG2, human-mouse chimeric
human IgG2 and humanised IgG2 have
been previously studied using X-ray or
neutron solution scattering or analytical
ultracentrifugation (8,14,15,19-27). The
recent studies of human monoclonal IgG1
and IgG4 utilised modelling to fit the
scattering curves in terms of molecular
structures (28,29). More accurate
3modelling for human IgG1 and IgG4 based
on joint X-ray and neutron scattering data
sets with Monte Carlo simulations has been
performed using a newly developed
workflow termed SASSIE (30,31). The
outputted structures are atomistic in their
nature, because they are physically-realistic
models with correctly-joined amino acid
and glycan residues. These outputs revealed
asymmetric solution structures that
resembled the IgG1 and (in part) the IgG4
crystal structures. Here, we used joint small
angle X-ray and neutron scattering (SAXS
and SANS), analytical ultracentrifugation
(AUC) and Monte Carlo modelling to
analyse 123,371 physically-realistic IgG2
structures. The resulting best-fit atomistic
models revealed that classical IgG2
possesses a Y-shaped symmetric
conformation in solution. This outcome
explained in structural terms for the first
time the different IgG2 isoforms and the
ligand binding functions of IgG2 to C1q
and the three human FcγR receptors. 
Results
Purification and characterisation of IgG2
Human IgG2 from myeloma plasma
were subjected to Superose 6 gel filtration
to ensure that this was monodisperse
immediately prior to AUC, SAXS and
SANS experiments. It was eluted as a large
main peak at approximately 16 ml, with a
minor peak at 14.5 ml that was discarded
(Figure 3). Non-reducing and reducing
SDS-PAGE gels were ran for IgG2, IgG1
6a, IgG1 19a and IgG4 B72.3. A single
band in lane 2 between 200 and 116 kDa in
non-reducing SDS-PAGE corresponds to
the expected mass of 147.4 kDa for intact
IgG2. Under reducing conditions in lane 3,
the heavy chains were observed at an
apparent molecular mass of 55.4 kDa, and
the light chains were observed between
21.5 and 31 kDa, both as expected (Figure
3). The corresponding non-reducing and
reducing samples for the other antibodies
IgG1 6a, IgG1 19a and IgG4 B72.3 were
also consistent with previous studies,
noting that IgG4 forms trace amount of a
half-molecule (28,29).
Native and deglycosylated
myeloma IgG2 was subjected to native
mass spectrometry in order to determine its
molecular mass size range. The mass
spectra show that native and deglycosylated
IgG2 existed as three main populations. For
native IgG2 (Figure 4A), the masses for the
three populations were 154,527 ± 52 Da,
156,392 ± 139 Da and 157,988 ± 62 Da.
The observed molecular masses were
higher than the calculated molecular mass
of 147.4 kDa from the sequence of IgG2
anti-LINGO1 Li33 (Figure 2), suggesting
polydispersity arising from variable protein
and glycan contents, but as this spanned
3,461 Da (2.2%) in mass, this
polydispersity was comparatively low. The
amounts of the three species were 8.9% for
154.5 kDa, 48% for 156.4 kDa and 43.1%
for 158.0 kDa. The high mass error range
was attributed to the different glycoforms
present in native IgG2. For deglycosylated
IgG2 (Figure 4B), the signals were clearer
with reduced error ranges. The masses and
corresponding distributions for the three
populations were decreased by 3,199 Da to
151,405 ± 4 Da (37.2%), 153,101 ± 3
(43.7%) and 154,805 ± 10 (19%), again
spanning 3,400 Da in mass. The reduction
was attributed to the removal of two
biantennary glycan chains at Asn297 (each
of approximate mass ~2200 Da) through
PNGase digests. Compared to IgG2 anti-
LINGO1 Li33 as a baseline, the protein
molecular masses of the three species were
increased by up to 4.0-10.6 kDa (2.7-7.2%).
Analytical ultracentrifugation of IgG2
The size and shape of IgG2 was
examined using sedimentation velocity
runs in AUC experiments. The SEDFIT
analyses involved fits of up to 300 scans.
Excellent agreement between the
experimental boundary scans and fitted
lines was seen (left panels, Figure 5). The
size distribution analyses c(s) for IgG2
showed a major monomeric species in
4solution, and accompanied by a negligible
dimer peak (right panels, Figure 5). The
monomer peak was observed at mean s020,w
values of 7.33 ± 0.07 S for IgG2 in H2O and
7.07 ± 0.20 S in 2H2O, within error of each
other (Figure 6A). These s020,w values were
comparable with values of 6.4–7.0 S
previously reported for IgG2
(8,14,15,19,20), but not with the value of
5.4 S reported in one study (21). These
previous studies did not state the protein
partial specific volume, and the buffer
density and viscosity in use, thus explaining
small differences with earlier s020,w values.
Some variation is attributed to instrumental
effects; the s020,w values from 67 different
laboratories showed a ±4.4% deviation in
an AUC study of reproducibility (30).
Given that the IgG2A/B and IgG2B
isoforms possess different hinge disulfide
bonds (8-10), the appearance of a single
c(s) peak indicated that, if present, these
two other isoforms showed similar shapes
to the classic IgG2A structure.
Given the scatter in s020,w values
(Figure 6A), the sedimentation rates of
IgG2 did not display a clear dependence on
sample concentration or buffer, indicating
that the overall shape remained unchanged
(Figure 6A). Thus the mean s020,w values in
H2O were only slightly reduced with
increase in NaCl concentration, being 7.40
± 0.02 S, 7.32 ± 0.02 S and 7.26 ± 0.06 S
for PBS-50, PBS-137 and PBS-250
respectively. The corresponding mean s020,w
values in 2H2O were 7.24 S, 7.07 ± 0.31 S
and 7.04 ± 0.07 S for PBS-50, PBS-137 and
PBS-250 respectively. The mean IgG2
dimer s020,w values in H2O were 11.1 ± 0.9
S, 10.3 ± 0.3 S and 11.3 ± 0.3 S for PBS-50,
PBS-137 and PBS-250 respectively. The
mean s020,w values observed in 2H2O were
10.6 S, 11.2 ± 0.6 S and 12.3 ± 1.0 S for
PBS-50, PBS-137 and PBS-250
respectively (Figure 6A). Given that protein
partial specific volumes v are affected by
the hydration shell (33,34), and that the
hydration shell for 2H2O has a higher mass
than that for H2O, the v values will be
reduced in 2H2O. The heavy water v value
of 0.70 ml/g in place of 0.73 ml/g for light
water proved sufficient to account for the
s020,w values. Thus for H2O, the overall
average s020,w values were 7.33 ± 0.07 S and
10.95 ± 0.69 S for IgG2 monomer and
dimer respectively. In 2H2O, the overall
average s020,w values were similar at 7.07 ±
0.20 S and 11.61 ± 0.99 S for IgG2
monomer and dimer respectively.
Heavy water is a promoter of dimer
formation and aggregates, and small
increases in IgG2 dimer were seen for the
2H2O samples. To examine this for IgG2,
the mean proportion of monomer for H2O
were 97.2 ± 1.0%, 96.3 ± 0.7% and 96.8 ±
1.1% for PBS-50, PBS-137 and PBS-250
respectively (Figure 6B). For 2H2O, the
mean amount of monomer were 95.4%,
96.8 ± 0.3% and 93.4 ± 2.1% for PBS-50,
PBS-137 and PBS-250 respectively. In
H2O, the mean value of 96.8 ± 0.5%
decreased to 95.2 ± 2.1% for the IgG2
monomer in 2H2O. The mean proportion of
dimers were 2.8%, 3.7 ± 0.7% and 3.2 ±
1.1% for PBS-50, PBS-137 and PBS-250
respectively in H2O (Figure 6B). These
showed small increases in 2H2O to 4.6%,
3.2 ± 0.3% and 6.6 ± 2.1% for PBS-50,
PBS-137 and PBS-250 respectively. For the
IgG2 dimer in H2O buffer, the mean value
of 3.2 ± 0.5% increased to 4.8 ± 2.1% in
2H2O buffer. High salt may have promoted
dimer formation in PBS-250 in 2H2O.
The masses from the c(s) analyses
compared well with the composition-
calculated and mass spectrometry values.
The c(s) masses were 155 ± 18 kDa, 163 ±
6 kDa and 147 ± 13 kDa for PBS-50,
PBS-137 and PBS-250 respectively in H2O.
Those for 2H2O were 141 kDa and 145 ± 17
kDa for PBS-50 and PBS-137 (not
available in PBS-250). These values agreed
with the expected molecular mass of 147.4
kDa calculated from the IgG2 composition
and those of 151 – 158 kDa determined by
native mass spectrometry. For the dimer,
the mean masses were doubled as expected
5at 282 ± 6 kDa, 274 ± 6 kDa and 284 ± 19
kDa for PBS-50, PBS-137 and PBS-250
respectively in H2O. In 2H2O, while the
errors were greater for reason of low
intensities, the mean masses were similar at
251 kDa, 285 ± 13 kDa and 219 ± 27 kDa
for PBS-50, PBS-137 and PBS-250
respectively, and were consistent with the
expected composition-calculated mass of
297.4 kDa for the dimer. These agreements
validated the use of myeloma IgG2 in the
SAXS and SANS analyses.
X-ray and neutron scattering data for
IgG2
The IgG2 solution structure was
jointly analysed by both SAXS and SANS
as complementary approaches (Table 1).
SAXS monitored the shape of the hydration
shell surrounding IgG2 as well as its overall
antibody structure, while SANS using
heavy water buffer monitored the overall
shape of the unhydrated structure because
the hydration shell was largely invisible in
this buffer (32).
SAXS was used to examine IgG2 at
0.5-4.0 mg/ml at 20°C in PBS-50, PBS-137
and PBS-250, using time-frame analyses to
ensure the absence of radiation damage
effects. Overall and cross-sectional Guinier
analyses resulted in high-quality linear
plots in three distinct regions of the I(Q)
curves, as expected for antibodies, from
which the Rg, Rxs-1 and Rxs-2 values were
obtained within satisfactory Q.Rg and Q.Rxs
limits (Figure 7A-C), as in our previous
studies (28,29). The lowest Q values were
not used in the Guinier Rg fits to minimise
any potential effect of trace aggregates in
the samples. The X-ray Rg values showed
an apparent concentration dependence.
These increased with concentration from
5.24 nm to 5.71 nm for PBS-50, 5.02 nm to
5.41 nm for PBS-137 and 5.16 nm to 5.38
nm for PBS-250 (Figure 8A). This increase
was attributed to X-ray radiation-induced
damage of IgG2, because a small increase
in intensities was seen in I(Q) at low Q
values, and because this concentration
effect was not seen in the AUC and neutron
data (Figures 6A, 8B). SAXS data above
1.5 mg/ml were thus discarded for reason of
radiation damage. The Rxs-1 and Rxs-2 values
were unchanged (Figure 8A). The average
Rxs-1 values were 2.64 ± 0.03 nm, 2.59 ±
0.04 nm and 2.61 ± 0.03 nm, and the
average Rxs-2 values were 1.41 ± 0.06 nm,
1.34 ± 0.08 nm, and 1.34 ± 0.04 nm, for
PBS-50, PBS-137 and PBS-250 buffers
respectively. The Rg, Rxs-1 and Rxs-2 values
in the three buffers were within error of
each other. The Rg values of 5.0-5.2 nm
here agreed with the earlier Rg values of 5.0
to 5.8 nm for humanised IgG2 (26), and
were slightly larger than those for
humanised IgG2 of 4.76 ± 0.048 nm
(20,25), panitumumab of 5.1 nm (22) and
polyclonal human IgG2 of 4.8 nm (27).
SANS was also used to examine
IgG2 at 0.3–4.0 mg/ml at 20°C in PBS-50,
PBS-137 and PBS-250 in 2H2O. Likewise,
the neutron Guinier analyses also revealed
high-quality linear plots in three distinct
regions of the I(Q) curves from which the
Rg, Rxs-1 and Rxs-2 values were obtained
within satisfactory Q.Rg and Q.Rxs limits
(Figure 7D-F). The Rg, Rxs-1 and Rxs-2 values
were consistent within error (Figure 8B).
The mean Rg values were 4.93 ± 0.07 nm,
4.97 ± 0.07 nm and 4.88 ± 0.09 nm, the
average Rxs-1 values were 2.30 ± 0.09 nm,
2.44 ± 0.02 nm and 2.36 ± 0.03 nm, and the
average Rxs-2 values were 0.91 ± 0.13 nm,
1.16 ± 0.05 nm and 0.93 ± 0.12 nm, for
PBS-50, PBS-137 and PBS-250
respectively. These neutron Rg, Rxs-1 and
Rxs-2 values were lower than those for X-
rays, this being attributed to the near
invisibility of the surface hydration shell in
heavy water, as well as the high negative
solute-solvent contrast difference
compared to that of IgG2 (34). The Rg
values reported here were slightly larger
than that of 4.76 ± 0.06 nm for human anti-
streptavidin IgG2 in 10 mM sodium acetate
(pH 5.2) in 2H2O (23).
6The distance distribution function
P(r) provided structural information on
full-length human IgG2 in real space, this
being equivalent to a histogram of all the
inter-atom distances within IgG2. The X-
ray P(r) analyses gave Rg values similar to
those from the X-ray Guinier analyses,
showing that the two analyses were self-
consistent (filled and open symbols in
Figure 8A). The maximum length L of IgG2
was determined to be 18 nm from the value
of r when the P(r) curve intersected zero at
large r (Figure 9A). This L value agreed
with the maximum dimension (Dmax) values
of 17.2 ± 0.7 nm and 17.3 ± 0.4 nm for
humanised IgG2 (25). The maxima in the
P(r) curves corresponded to the most
frequently occurring interatomic distances
within the structure. Two peaks, M1 and
M2, were identified in all the P(r) curves at
r values of 4.8 ± 0.3 nm and 7.6 ± 0.3 nm
respectively. The M1 peak corresponds to
distances within each Fab and Fc region,
while the M2 peak corresponds to distances
between the Fab-Fab and Fab-Fc regions.
No concentration dependence in the M1 and
M2 positions was observed (Figure 9C).
The neutron P(r) analyses of IgG2
in heavy water revealed similar Rg values
compared to the Guinier analyses (filled
and open symbols in Figure 8B). The
majority of L values were 17 nm except for
0.59 and 2.38 mg/ml of IgG2 in PBS-50
(average L of 16.9 ± 0.4 nm) (Figure 9B).
The M1 and M2 peaks were observed for
most of the P(r) curves except for 0.33
mg/ml IgG2 in PBS-250, and showed r
values of 4.8 ± 0.5 nm and 7.6 ± 0.3 nm
respectively. The neutron and X-ray M1
and M2 values were in excellent agreement,
and the reduced neutron L values in
comparison to the X-ray L values was
attributed to the hydration shell being not
visible in neutron scattering.
Scattering models for IgG2
The IgG2 starting model was
generated using the crystal structures of the
human IgG2 Fab and Fc regions
(Experimental Procedures). Residues
missing in the Fc region were replaced with
the corresponding residues from the other
heavy chain (Experimental Procedures).
The starting structure was Y-shaped with
the Fab arms crossed over one another. This
starting structure was energy minimised
using NAMD (Experimental Procedures).
In the Monte Carlo simulations
based on backbone dihedral angles, the 19
IgG2 residues (Figure 2E) represented the
full-length hinge which was assigned to be
flexible (Figure 1) and was varied in four
different simulations (Experimental
Procedures). The first search involved
200,000 simulations to yield 106,799
sterically-accepted models that included
asymmetric as well as symmetric IgG2
models. The second, third and fourth
searches reduced the maximum rotation
angle per step from 30° to 15° to include
smaller movements of the IgG2 hinge.
These involved distance constraints of 1 nm
or 0.75 nm between the α-carbons of each 
of the four cysteine residue pairs that form
hinge disulfide bonds (Figure 1). A total of
100,000 simulations were carried out for
each of these two distance constraints using
five different starting structures (20,000
simulations for each structure). This
resulted in 12,597 and 3,975 accepted
models for distance constraints of 1 nm and
0.75 nm respectively. Different asymmetric
and symmetric IgG2 starting structures with
or without crossed-over Fab regions
explored four types of Fab arrangements,
limited any biased structures that favour
certain conformations, and allowed the
sampling of the maximum conformational
space. Overall, 123,371 models were
accepted for evaluation from a total of
400,000 simulated ones.
X-ray scattering modelling fits for IgG2
The 123,371 models were converted
to their hydrated small-sphere
representations for comparison with the
SAXS curves. Their Rg values ranged
between 3.85 – 6.21 nm (Figure 10A,B;
7Table 2). The Rxs-1 and Rxs-2 ranges were
1.34 – 3.36 nm and 0.02 – 2.30 nm
respectively. The models thus covered a
broad range of conformational space as
desired (grey, Figure 11A). Following an
examination of the R-factors, the
experimental X-ray curves used for the fits
were taken to be those for 0.5 mg/ml, 1.0
mg/ml and 1.5 mg/ml of IgG2 in PBS-50,
PBS-137 and PBS-250 respectively, for
which radiation damage was seen to be
minimal. The scattering curve fits gave rise
to a wide range of R-factors from 3.5% to
22.9% in a V-shaped distribution with its
minimum close to the experimental Rg
value (grey, Figure 10A,B). The lowest R-
factors for the three X-ray scattering curves
in PBS-50, PBS-137, PBS-250 were 4.0%,
3.5% and 3.6% respectively, showing that
these structures were improved compared
to the starting IgG2 structure R-factors of
5.1%, 4.8% and 5.1%. The use of R-factor
cut-offs of 5.5%, 5.0% and 5.7% as filters
resulted in the selection of 35,141, 30,088
and 42,292 good-fit models for the three
scattering curves in PBS-50, PBS-137 and
PBS-250 buffers respectively (orange,
Figure 10A,B; Table 2) and reduced the
number of accepted models by two-thirds.
Views of the 30,088 models for 1 mg/ml
IgG2 in PBS-137 showed a broad
conformational distribution (gold, Figure
11B).
The α-carbon disulfide distance 
constraints of 0.75 nm greatly limited the
possible Rg values of the structures. When
the 123,371 models were filtered for
distances of ≤ 0.75 nm between the four 
cysteine pairs (blue, Figure 10A,B), only
5,242 models remained (cyan and blue,
Figure 11E). After the R-factor filters were
applied to the 5,242 models for each of the
PBS-50, PBS-137 and PBS-250 curves, this
left 1,474, 1,247 and 1,100 models
respectively (Table 2). The fit of the best-fit
IgG2 model with the lowest R-factor for
each X-ray experimental curve showed
good visual agreements out to a Q value of
1.1 nm-1 (Figure 12A-C); note that the same
best-fit model was identified for the X-ray
fits in PBS-50 and PBS-250, in agreement
with the observed lack of conformational
change in these buffers. The M1 and M2
values of the X-ray best-fit structures in
Figure 12A-C were 4.0 nm and 7.7 nm, in
good agreement with the observed values of
4.8 ± 0.3 nm and 7.6 ± 0.3 nm (Figure 9C).
Also, the P(r) curves for the best-fit models
showed a smaller L value of 15-16 nm
compared to the experimental L value of 18
nm.
The d1 value represented the
separation between the centres of the two
Fab regions (Figure 1). The min(d2,d3) and
max(d2,d3) values represented the
minimum and maximum separation
between the centres of each Fab-Fc pair (d2
and d3). The 123,371 models covered a
large range of d1, min(d2,d3) and
max(d2,d3) values, in reflection of the
asymmetric and symmetric nature of the
IgG2 models. After the R-factor and α-
carbon disulfide distance filters were
applied, the ranges of d1, min(d2,d3) and
max(d2,d3) distances were much reduced
to similar values of 5.6-7.5 nm, 6.8-8.4 nm
and 7.6-8.9 nm in the three fits (Table 2).
The reductions were explained by a
convergence to a single best-fit
conformational ensemble in the PBS-50,
PBS-137 and PBS-250 buffers. The d1
distances were also smaller than the
min(d2,d3) distances, indicating that the
distance and angle between the two Fab
regions is smaller than the Fab-Fc angles
(Table 2). The min(d2,d3) and max(d2,d3)
ranges overlapped. These considerations
indicated that the best-fit IgG2 models
adopted a largely symmetric Y-shape
structure according to the X-ray modelling
fits.
Neutron scattering modelling fits for IgG2
The 123,371 models were converted
to their unhydrated small-sphere
representations for comparison with the
SANS curves. Their Rg values ranged
between 3.77 and 5.70 nm (Figure 10C,D;
8Table 2). The Rxs-1 and Rxs-2 ranges were
1.55 – 2.96 nm and 0.05 – 2.14 nm
respectively. The modelled Rg, Rxs-1 and Rxs-
2 values were smaller than those for the
corresponding X-ray Rg, Rxs-1 and Rxs-2
values because of the invisibility of the
hydration shell using neutrons in heavy
water. Following an R-factor examination
of the available experimental scattering
curves with three to five different
concentrations in PBS-50, PBS-137 and
PBS-250 in heavy water, the best
experimental neutron curves were taken to
be 0.45 mg/ml, 1.0 mg/ml and 1.99 mg/ml
IgG2 in PBS-50, PBS-137 and PBS-250
respectively. The R-factor cut-offs were
3.75% for 1 mg/ml IgG2 in PBS-137 and
6% for 0.45 mg/ml IgG2 in PBS-50 when
these two curves were compared (Table 2).
When the curve for 1.99 mg/ml IgG2 in
PBS-250 was compared to 0.45 mg/ml of
IgG2 in PBS-50 (100% 2H2O), the R-factor
cut-off was 8.6 %. This R-factor cut-off was
too lenient, giving 57,566 models, thus this
was reduced to 8.2 %, giving 35,215
models (Table 2). The lowest R-factors for
the three scattering curves in PBS-50, PBS-
137, PBS-250 buffers were 4.15%, 2.85%
and 6.13% respectively, which were again
improved compared to the starting IgG2
structure values of 6.1%, 4.0% and 8.6%.
The R-factor cut-off filters resulted in
44,835, 10,731 and 35,213 models
respectively (red, Figure 10C,D, Table 2).
The 10,731 models for 1 mg/ml IgG2 in
PBS-137 showed a broad conformational
distribution (Figure 11C). The modelled Rg
minima was centered on the experimental
Rg value, thus showing good agreement
(red, Figure 10C,D).
  The α-carbon disulfide distance 
constraints of 0.75 nm resulted in only
5,242 models remaining out of 123,371 (see
above) (Figure 11E). After filtering for R-
factors, 13, 13 and 19 models remained for
the three curves in PBS-50, PBS-137 and
PBS-250 respectively (yellow, Figure
10C,D; Table 2). The best-fit IgG2 models
with the lowest R-factor for the three
buffers agreed with the experimental
neutron curves up to a Q-value of 1.0 nm-1
(Figure 12D-F). The P(r) curves were in
good agreement when overlaid, although a
smaller L value of 15 nm was seen
compared to the experimental L value of 17
nm. The M1 and M2 values of the neutron
best-fit structures in Figure 12D-F were 4.0
nm and 7.5 nm, in good agreement with the
observed values of 4.8 ± 0.5 nm and 7.6 ±
0.3 nm (Figure 9D). Surprisingly, this
turned out to be the same IgG2 model in all
three fits. The R-factor of 3.5% for PBS-
137 was the lowest of the three.
The application of the joint R-
factor cut-off filter and the 0.75 nm α-
carbon disulfide distance constraints to the
SANS modelling restricted the range of d1,
min(d2,d3) and max(d2,d3) distances in a
similar fashion to the SAXS modelling
(Table 2). After the R-factor and disulfide
distance filters were applied, far fewer
neutron models were acceptable (13-19
models) compared to the X-ray models
(1,100-1,474 models). The ranges of d1,
min(d2,d3) and max(d2,d3) distances were
altered to similar values of 6.4-7.4 nm, 7.5-
8.1 nm and 7.9-8.7 nm respectively in the
three fits compared to X-rays (Table 2). The
neutron d1 values of 6.4-7.4 nm were
higher than those for X-rays of 5.6-7.5 nm,
although these ranges overlapped,
suggesting that the IgG2 structures with
wider Fab regions were favoured in the
neutron fits. The range of neutron d1 values
was narrower than for the X-ray d1 values.
Interestingly, the min(d2,d3) and
max(d2,d3) distances of the three sets of
filtered neutron models were consistent
with each other, and the ranges overlapped.
It was concluded from the neutron
modelling that IgG2 adopted a symmetric
Y-shape structure, in agreement with the X-
ray modelling.
Joint X-ray and neutron best-fit IgG2
models
The final best-fit models were
identified by using both the SAXS and
9SANS R-factor cut-offs and the disulfide α-
carbon distance constraints of ≤ 0.75 nm as 
filters. Compared to the distributions of the
30,088 and 10,731 best-fit models for the
X-ray and neutron R-factor cut-off filters
respectively (Figure 11B-C), the
application of both R-factor cut-off filters
reduced the best-fit models to 4,866
(brown, Figure 11D). These 4,866 IgG2
models showed Fab regions that
encompassed the majority of
conformational space around the Fc region.
The α-carbon disulfide distance constraint 
of ≤ 0.75 nm had severely restricted the 
allowed positions of the Fab regions around
the Fc region (Figure 11E). When the
SAXS and SANS R-factors and disulfide
distance constraints were jointly applied,
the number of IgG2 best-fit models were
reduced to 13, 13 and 19 models for PBS-
50, PBS-137 and PBS-250 respectively
(Table 2). The 13 best-fit models for PBS-
137 adopted a symmetrical Y-shape (Figure
11F). Overall, nine best-fit IgG2 models
fitted all six SAXS and SANS experimental
I(Q) and P(r) curves in PBS-50, PBS-137
and PBS-250. This outcome indicated little
or no differences in the IgG2 solution
structures in three salt concentrations or
between light and heavy water. This agreed
with the AUC analyses (Figure 6A).
Dimensionless Kratky plots of
(Q.RG)2.I(Q)/I(0) vs Q.RG provided
information on the folded state and
flexibility of IgG2 (Figure 12G-L). They
showed a characteristic two-peak curve
similar to that previously (24). The X-ray
data offered better signal-to-noise ratios
than the neutron data. Comparison between
the best-fit modelled and experimental
Kratky plots showed good agreement up to
a Q.RG of 6 for X-rays and 4 for neutrons.
The increased X-ray intensities beyond
Q.RG of 6 was attributed to potential
flexibility in the IgG2 structure that had not
been considered in the modelling. A similar
intensity increase beyond Q.RG of 4 for
neutrons may also indicate flexibility, but
may also include a flat background due to
incoherent scattering contribution that had
not been discounted.
The s020,w values of the nine
scattering best-fit models were calculated
using HYDROPRO (Experimental
Procedures) in order to compare these with
the experimental values (Figure 6A). Using
the density (1.00529 g/ml) and viscosity
(0.01002 poise) parameters for PBS-137
buffer at 20 ºC and a partial specific volume
of 0.7 ml/g, the mean s020,w value was 7.04
± 0.05 S, which was less than that of 7.32 ±
0.02 S seen experimentally. The energy
minimised IgG2 starting structure prior to
the Monte Carlo simulations gave an s020,w
value of 7.10 S. This difference in s020,w
values suggested that the best-fit IgG2
scattering model was slightly more
elongated in its solution structure than the
starting IgG2 structure.
Discussion
The X-ray and neutron scattering
data for human myeloma IgG2, coupled
with atomistic Monte Carlo simulations of
the dihedral angles in the mainchain
backbone, have revealed novel molecular
details of its solution structure. Importantly,
this provided the first molecular
explanation of the different functional IgG2
interactions with its protein ligands.
Comprehensive data sets were obtained on
human myeloma IgG2 for reason of its
availability. Mass spectrometry and AUC
showed only a 2% range in mass and a
single c(s) peak respectively, thus the
polydispersity in these samples was low
and did not preclude molecular structure
analyses. The IgG2 structure was
unaffected in scattering experiments in
concentration series in three salt
concentrations and in light and heavy water.
The IgG2 modelling was based on separate
crystal structures for the Fab and Fc regions
to generate a starting model that was refined
by energy minimisation and subjected to
dihedral angle Monte Carlo modelling.
Three filters based on the X-ray data,
neutron data and disulfide distances in the
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hinge region identified nine best-fit
structures. The resulting ‘classical’ human
IgG2 revealed a symmetric Y-shaped
conformation in solution that was able to
account for its different functional
interactions with complement C1q and the
FcγR receptors. 
Together, solution scattering and
Monte Carlo modelling have offered
molecular structural information on the
IgG1, IgG2 and IgG4 subclasses. The IgG2
starting structure included the full IgG2
hinge 220ERKCCVECPPCPAPPVAGP238.
Of the 123,371 physically-realistic IgG2
models derived from this hinge, the joint X-
ray and neutron best-fit strategy brought
down the number of filtered structures from
30,088 and 10,731 models respectively to a
joint total of 4,866 models (brown, Figure
13A). Thus the comparison of hydrated and
unhydrated scattering structures proved to
be effective. The further filter of ≤ 0.75 nm 
for the disulfide bridges between the four α-
carbon cysteine pairs in the hinge gave
5,242 permitted structures (blue, Figure
13A). The 13-19 best-fit models with the
lowest R-factors that passed the double
scattering and disulfide filters revealed that
human IgG2 adopts a Y-shaped symmetric
conformation in solution. The 13 best-fit
models for PBS-137 in light and heavy
water were shown (black, Figure 13A), of
which nine models at d1 of approximately
7 nm fitted all the X-ray and neutron
scattering curves from six different buffers.
These nine structures are available in
Supplementary Material, alongside their
computed scattering curves and the
experimental data.
Similar methods were used to
determine the solution structures of human
monoclonal IgG1 and IgG4 by joint X-ray
and neutron Monte Carlo scattering fits
(31). That work identified two α and β 
clusters of symmetric and asymmetric
structures respectively. The clusters were
defined by d1 distances of ≤ 7 nm or ≥ 7 nm 
for the α and β clusters respectively (Figure 
13B). The best-fit models of IgG1
corresponded to the β cluster of asymmetric 
structures, and this agreed with the crystal
structure of intact human IgG1 b12 (red,
Figure 13B). The best-fit models of IgG4
B72.3 corresponded to both the α cluster of 
symmetric structures and β cluster of 
asymmetric structures (blue, Figure 13B).
Interestingly the IgG2 best-fit models did
not correspond to either of the best-fit
clusters for IgG1 or IgG4, and instead were
located between these at d1 = 7 nm (black,
Figure 13B). The three analyses indicated
that these three IgG subclasses show
different conformations. This outcome
explains the evolution of the human IgG
subclasses such that human IgG1, IgG2 and
IgG4 exhibit distinct structural and
functional properties. IgG1 and IgG4 have
two Cys-Cys bridges in their hinges, while
IgG2 has four Cys-Cys bridges; in addition
IgG2 lacks a second Gly residue in its hinge
that is present in IgG1 and IgG4 (35,36).
Furthermore IgG2 has a shorter hinge than
IgG1 and IgG4 (Figure 2H). These three
features are expected to make the IgG2
hinge more rigid compared to the IgG1 and
IgG4 hinges, and alter its function. For
example, it can now be seen why IgG2 is
able to perform a unique structural role as
the only IgG subclass that binds
predominantly to bacterial capsular
polysaccharide antigens (2,3).
The outcome of scattering
modelling and the number of best-fit
models depends on the inputs, i.e. the
quality of the experimental scattering
curves, the starting model, and the number
of Monte Carlo models and their filtering.
Each are discussed in turn. (i) For example,
the lowest X-ray R-factors for IgG2 of 4.2-
4.7% were higher than those for IgG1 of
2.6-2.9% and IgG4 of 2.5-2.6% (31). This
difference is attributable to the larger Q-
range of 0.13 - 2 nm-1 used for IgG2 here
(with higher noise at larger Q values),
whereas these Q-ranges were lower at 0.09
– 1.1 nm-1 and 0.15 – 1.1 nm-1 for IgG1 and
IgG4 respectively. Nonetheless, all three
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studies resulted in R-factor vs. Rg graphs
with clear minima that identified an
ensemble of best-fit structures. The final Rg
values of the IgG2 models of 4.8 nm (Table
2) were similar to those of 4.9 nm for IgG4,
but less than that of 5.2 nm for IgG1 (31).
(ii) The assumptions used for generating the
initial models can be important. For
example, the earlier neutron scattering fits
for human monoclonal anti-streptavidin
IgG2 employed an IgG2 starting model
based on the crystal structure of full-length
mouse IgG2A with three Cys residues in the
hinge and not four (PDB code 1IGT) and
two Gly residues in its hinge, and only
varied three amino acids in the IgG2A
upper hinge to generate 56,511 acceptable
models (23). Unsurprisingly these authors
determined an asymmetric IgG2 structure.
In the current study, Fab and Fc crystal
structures for human IgG2 were used
alongside variation of the full-length human
IgG2 hinge with all 19 residues, including
four Cys residues in the hinge and only a
single hinge Gly residue (Figure 2E). The
current study resulted in symmetric IgG2
structures that well explained the biological
function of IgG2 (see below). Further
structural analyses with monoclonal IgG2
will clarify these differences further. (iii) A
large number of starting models facilitated
the identification of best-fit structures.
Starting from 704,000, 700,000 and
400,000 trial models for IgG1, IgG4 and
IgG2 respectively, the numbers of
evaluated physically realistic models with
no steric overlap were 231,492 (IgG1),
190,437 (IgG4) and 123,371 (IgG2). These
resulted in final totals of 28, 2,748 and 13
best-fit structures respectively (Figure
13B). The joint X-ray and neutron fits was
the key filter in reaching the final 28 models
for IgG1, while the joint X-ray and neutron
fits together with the disulfide separation
filters were key in reaching the final nine
best-fit models for IgG2. The rather larger
number of final best-fit IgG4 models
resulted from the relatively unrestricted
shorter IgG4 hinge conformation that gave
many more compatible models.
There are three different isoforms of
IgG2, namely IgG2A (classical), IgG2A/B
and IgG2B, which are found in both human
monoclonal IgG2 and myeloma-derived
IgG2 (8-10). The isoforms vary in the
disulfide bond connectivity in the IgG2
hinge, where these studies suggested that
the two Cys223-Cys223 and Cys224-
Cys224 disulfide bonds between the two
heavy chains (Figure 1) can be broken with
the formation of new disulfide bonds with
the Fab regions. The light and heavy chains
in the Fab region are connected by a
Cys135-Cys214 bridge (Figure 1). In the
IgG2B isoform, Cys223 from one heavy
chain can form an interchain disulfide bond
with the C-terminal Cys214 in the light
chain. Cys224 from one heavy chain can
form an interchain disulfide bond with
Cys135 in the other heavy chain (10,37-40)
or an intrachain disulfide bond with Cys135
in the same heavy chain (8,41). Also,
Cys223 can form an intrachain disulfide
bond with Cys135 in the same heavy chain
where Cys224 forms an interchain disulfide
bond with Cys214 in the light chain (9). The
disulfide bond variations in IgG2A/B and
IgG2B are still not fully understood, and the
impact of these different disulfide bond
variants upon antigen binding as well as
effector functions is currently unknown.
Although no SAXS and SANS data
were collected on the individual IgG2A/B
and IgG2B isoforms, our IgG2 best-fit
models for human IgG2 provided new
insight into these two other isoforms
formed by potential Cys223-Cys214 and
Cys224-Cys135 bridges. These alternative
disulfide arrangements may result in more
compact global structures than the classic
IgG2A isoform (8,40). Interestingly, both
these disulfide bond variants were indeed
found in our library of 123,371 IgG2
models. Thus 53 models showed α-carbon 
separations below 0.75 nm for Cys223-
Cys214, and another 126 showed
separations below 0.75 nm for Cys224-
Cys135. However, none of these models
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satisfied the joint X-ray/neutron R-factor
cut-off filter and the interchain disulfide
separation of below 0.75 nm for the best-fit
IgG2 models, showing that their structures
were distinct from that of IgG2 in its IgG2A
isoform as studied. The above 53 models
gave R-factors of 5.1–16.2 % for X-rays
and 4.6–15.9 % for neutrons, both in PBS-
137. The above 126 models gave R-factors
of 4.9–8.9 % for X-rays and 4.3–11.0 % for
neutrons. In comparison, the best overall R-
factor was lower at 3.5% for IgG2 (Table
2). The s020,w values of the 53 and 126
models were 7.2 ± 0.2 S and 7.2 ± 0.1 S
respectively, which were not much
different from the experimental value of
7.32 ± 0.02 S in PBS-137 and the best-fit
modelled value of 7.04 S above. While a
small difference of about 0.3 S was seen
between IgG2A and IgG2B, this difference
was considered to be low. Overall, even
though the IgG2A/B and IgG2B isoforms
showed different solution structures, they
were not more compact than the classic
IgG2A isoform.
A Y-shaped symmetric structure of
IgG2 (or IgG2A) had been determined by
our atomistic modelling. This outcome
differs from the postulated moderately
asymmetric structures for the IgG2A and
IgG2B isoforms based on comparison with
the asymmetric IgG1 crystal structure
(8,11), and the asymmetric structures
reported elsewhere from electron
microscopy and neutron scattering (18,23).
By electron microscopy, the conclusion of
asymmetric IgG2 structures was attributed
to the study of an assumed IgG2A/B
structure with an asymmetric disulfide
arrangement at its hinge (18). The
differences from the previous neutron
scattering modelling that gave an
asymmetric solution structure could arise
from the use of the mouse IgG2a crystal
structure to fit the neutron data instead of a
human IgG2 Fab and Fc structure (23). In
that study, the neutron data on human anti-
streptavidin IgG2 were measured at high
concentration in non-physiological buffers
containing 10 mM sodium acetate (pH 5.2),
which may have caused conformational
changes, while here we have used more
dilute concentrations for our AUC runs as
well as our X-ray and neutron data
collection, all at pH 7.4.
The atomistic best-fit models for
human IgG2 provided new molecular
insight into its binding to the FcγRII and 
FcγRIII receptors, but not to C1q of 
complement nor to the FcγRI receptor. This 
key assessment was performed using
recently available crystal structures of the
Fc region of human IgG1 complexed with
these ligands (Figure 14). The C1q globular
head in complex with the IgG1-Fc region
(PDB code 6FCZ) (42) was aligned with the
nine best-fit models of IgG2 through their
Fc regions, giving a satisfactory rms
deviation of 0.149 nm in α-carbon 
positions. Clear steric clashes between the
C1q domains and the Fab2 region of IgG2
were visible, explaining why C1q cannot
bind to IgG2 (Figure 14A). The FcγRI 
(CD64) receptor in complex with the IgG1-
Fc region (PDB code 4X4M) (43) was also
aligned with the nine IgG2 best-fit models
through their Fc regions, resulting in an rms
of 0.168 nm (Figure 14B). Here, clear steric
clashes between the D1 and D3 domains of
the three-domain “sea-horse” FcγRI 
structure were visible with the Fab1 and
Fab2 regions of IgG2, explaining why IgG2
cannot bind to FcγRI. The views of Figure 
14A,B show that the Fab regions were too
close to the Fc region to permit C1q and
FcγRI binding. In addition, the IgG2 
sequence does not possess the key amino
acid contact residues required for the
complexes between the IgG2-Fc region and
each of C1q and FcγRI as revealed by their 
recent co-crystal structures (Figure 2E,F).
In distinction to these first two cases, the
dissociation constant KD of IgG2 with the
FcγRIIIA V158 receptor is 14 μM (44), 
showing that the IgG2-FcγRIIIA complex 
is formed, albeit weakly. To examine this,
the Fc region of the nine best-fit IgG2
models were aligned with three crystal
13
structures for the Fc-FcγRIII complex 
(PDB codes 3SGJ, 5VU0 and 5YC5) to
give satisfactory low rms values of 0.100
nm, 0.102 nm and 0.102 nm respectively
(45-47) (Figure 14C). The two orthogonal
views of the superimposed IgG2 complexes
with FcγRIIIA V158 show that these IgG2 
complexes with the two-domain receptor
were sterically compatible with the position
of the Fab regions, and were therefore
allowed. The ability of scattering modelling
to generate atomistic structures for the full-
length IgG2 molecules has provided
important clarifications of the ability of
IgG2 to bind to C1q and the Fc receptors.
Experimental Procedures
Purification and composition of IgG2
Purified myeloma IgG2 from
human plasma (Athens Research, Georgia,
USA) was further purified by gel filtration
using a Superose 6 10/300 column (GE
Healthcare) to remove aggregates, then
concentrated using Amicon Ultra spin
concentrators (50 kDa molecular mass cut-
off), and dialyzed at 4°C against its
ultracentrifugation and scattering buffers
(see below). The N-linked oligosaccharides
at Asn297 on the CH2 domains (Figure 1)
were represented as a complex-type
biantennary oligosaccharide with a Man3-
GlcNAc2 core and two
NeuNAc.Gal.GlcNAc antennae (48). Using
SLUV2 in the SCT software package, the
IgG2 molecular mass was calculated to be
147.4 kDa from the IgG2 sequence (Figure
2) based on the Fab and Fc crystal structures
(PDB codes: 3KYM and 4HAF
respectively), its unhydrated volume was
189.9 nm3, its hydrated volume was 231.0
nm3 (based on a hydration of 0.3g of water
per gram of glycoprotein and an
electrostricted volume of 0.0245 nm3 per
bound water molecule), its partial specific
volume v was 0.7294 ml/g and its
absorption coefficient at 280 nm was 15.33
(1%, 1 cm pathlength) (49).
All data were recorded in
phosphate-buffered saline with different
NaCl concentrations. The buffer with 137
mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl
and 1.5 mM KH2PO4 (pH 7.4) was termed
PBS-137. When 50 mM NaCl or 250 mM
NaCl were used, these were termed PBS-50
and PBS-250 respectively. Buffer densities
were measured using an Anton Paar DMA
5000 density meter, for comparison with
the theoretical values calculated by
SEDNTERP (50). This resulted in densities
of 1.00529 g/ml for PBS-137 at 20°C
(theoretical, 1.00534 g/ml), 1.00145 g/ml
for PBS-50 at 20°C (theoretical, 1.00175
g/ml), 1.0098 g/ml for PBS-250 at 20°C
(theoretical, 1.00998 g/ml), all in 100%
light water. A buffer viscosity of 0.01002
poise was used for the light water buffers.
The densities were increased to 1.11183
g/ml for PBS-137 at 20°C (theoretical,
1.11247 g/ml), 1.10839 g/ml for PBS-50 at
20°C (theoretical, 1.10889 g/ml), 1.116752
g/ml for PBS-250 at 20°C (theoretical,
1.11711 g/ml), all in 100% 2H2O. A
viscosity of 0.01200 poise was used for the
heavy water buffers.
Native mass spectrometry of IgG2
IgG2 was deglycosylated with
PNGase F (New England Biolabs, Herts.,
UK) according to the manufacturer’s
protocol. The native and deglycosylated
IgG2 samples were placed into spin
concentrators (Amicon Ultra 500, MWCO
50 kDa) pre-soaked with 200 mM
ammonium acetate (LC/MS grade water).
The samples were buffer exchanged into
200 mM ammonium acetate six times at
4°C in the spin concentrators. The samples
were ran on a Synapt G1 instrument
(Waters Corp., UK), the spectra were
analysed in MassLynx Version 4.1 mass
spectrometry software (Waters Corp., UK)
and mass calculations were performed in
Amphitrite Atropos (51). The experimental
acquisition parameters were as follows:
capillary voltage of 1.3kV, sampling cone
voltage of 175V, extraction cone voltage of
4.5V, backing pressure of 7 mbar, trap
collision energy of 40eV, and transfer
collision energy of 10eV. The mass range
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was 1,000-18,000 m/z. Proteins were
sprayed using nano-electrospray ionisation
from gold-coated capillaries prepared in-
house using a Flaming Brown P97 needle
puller and a Quorum Q150R S sputter
coater.
Sedimentation velocity data for IgG2
Sedimentation velocity data were
obtained on two Beckman XL-I analytical
ultracentrifuges equipped with AnTi50
rotors for IgG2 samples in PBS-50, PBS-
137 and PBS-250 at 20°C in each of 100%
H2O and 100% 2H2O. Data were collected
at rotor speeds of 40,000 r.p.m. in two-
sector cells with column heights of 12 mm.
Sedimentation analysis was performed
using direct boundary Lamm fits of up to
300 scans using SEDFIT (version 14.6)
(52,53). SEDFIT resulted in
size-distribution analyses c(s) that assumed
all species to have the same frictional ratio
f/f0. The final SEDFIT analyses used a fixed
resolution of 200 and optimized the c(s) fit
by floating f/f0, the meniscus and bottom of
the sedimentation boundaries until the
overall root-mean-square deviations (<
0.02) and visual appearance of the fits were
satisfactory. The percentage of oligomers in
the total loading concentration was derived
using the c(s) integration function. Partial
specific volumes of 0.73 ml/g and 0.70 ml/g
were used for samples in 100% H2O and
100% 2H2O respectively. HYDROPRO
version 10 was used to calculate the
sedimentation coefficients based on the
molecular structure of human IgG2 (54),
using an atomic level shell calculation and
a hydrodynamic radius of 0.29 nm of each
element in the model.
X-ray and neutron scattering data for
IgG2
X-ray scattering data were obtained
on Instrument BM29 at the European
Synchrotron Radiation Facility, Grenoble,
France (55). Data were acquired using a
Dectris Pilatus 1M detector with a
resolution of 981 × 1043 pixels (pixel size
of 172 µm × 172 µm). Sample volumes of
50 μl were loaded into polymerase chain 
reaction strip tubes for the BioSAXS
automatic sample changer (56). Each
sample in the quartz capillary was moved
continuously during beam exposure to
reduce radiation damage. Sets of ten time
frames, with a frame exposure time of 1 s
each, were acquired, alongside real-time
checks that confirmed the absence of
radiation damage during data acquisition.
After this, any frames containing radiation
damage were removed and the remaining
frames were averaged. EDNA software
provided automatic data processing in
which the intensities I(Q) were
automatically scaled by concentration (57).
The Biosaxs Customised Beamline
Environment (BsxCUBE) software was
used for control of the automatic sample
changer, and the sample settings were
loaded from the Information System for
Protein Crystallography Beamlines
database (ISPyB) (55,58). IgG2 samples
were studied in each of PBS-50, PBS-137
and PBS-250 at 20°C at eight
concentrations between 0.5-4.0 mg/ml in a
dilution series. Data for samples at above
1.5 mg/ml were not used due to radiation-
induced damage.
Neutron scattering data were
obtained on Instrument D22 at the Institut
Laue-Langevin, Grenoble, France. The data
were acquired using a two dimensional 3He
detector with 128 × 128 pixels of 7.5 × 7.5
mm2 in size. The sample-to-detector and
collimation distances were both 5.6 m. The
wavelength λ was 0.60 nm. Sample 
volumes of 400 μl were used. Samples were 
measured in rectangular Hellma cells of 2
mm thickness in a thermostatted sample
rack set at 20 °C. IgG2 was studied in PBS-
50, PBS-137 and PBS-250 in 100% 2H2O
buffers at 20 °C. The dialyses were
performed on site immediately prior to D22
experiments to reduce the risk of aggregate
formation. IgG2 concentrations were 0.30,
0.45, 0.59, 1.19 and 2.38 mg/ml for PBS-
50, 0.5, 1.0, 2.0, 3.0 and 4.0 mg/ml for PBS-
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137, and 0.33, 1.99 and 2.66 mg/ml for
PBS-250.
In a given solute–solvent contrast,
the radius of gyration Rg is a measure of
structural elongation if the internal
inhomogeneity of scattering densities
within the glycoprotein has no effect.
Guinier analyses at low Q (where Q = 4π 
sin θ/λ; 2θ is the scattering angle and λ is the
wavelength) give the Rg and the forward
scattering at zero angle I(0) (59):
This expression is valid in a Q.Rg range up
to 1.5. If the structure is elongated, the
mean radius of gyration of cross-sectional
structure Rxs and the mean cross-sectional
intensity at zero angle [I(Q)Q]Q→0 is
obtained from:
The cross-sectional plot for
immunoglobulins exhibits two distinct
regions, a steeper innermost one and a
flatter outermost one, (60) and the two
analyses correspond to Rxs-1 and Rxs-2,
respectively. The Rg and Rxs analyses were
performed using the SCT software package
(sas_curve_analysis.py) (45). The Q ranges
for the Rg, Rxs-1 and Rxs-2 values were 0.15-
0.28 nm-1, 0.31-0.47 nm-1 and 0.65-1.04
nm-1 respectively. Indirect Fourier
transformation of the scattering data I(Q) in
reciprocal space into real space to give the
distance distribution function P(r) was
carried out using the program GNOM
version 4.6 (61):
P(r) corresponds to the distribution of
distances r between volume elements. This
provides the maximum dimension of the
antibody L and its most commonly
occurring distance M in real space. For this,
the X-ray I(Q) curve utilized up to 1043
data points in the Q range between 0.03 nm-
1 and 4.92 nm-1. The neutron I(Q) curve
utilized up to 108 data points in the Q range
between 0.1 nm-1 and 1.7 nm-1.
Dimensionless Kratky plots of
(Q.RG)2.I(Q)/I(0) vs Q.RG were calculated
using the Guinier RG values to provide
information on the folded state and
flexibility of IgG2 (62-65).
Generation of starting structure of IgG2
A full-sequence starting model was
created for human IgG2 using two crystal
structures of the separate Fab and Fc
regions. That for human monoclonal
antibody IgG2 anti-LINGO1 Li33
represented the IgG2 Fab region (15) (PDB
code 3KYM). That for the human IgG2 Fc
region was used directly (16) (PDB code
4HAF). The EU numbering was used here
where Asn297 (Figure 1) is equivalent to
Asn297 in IgG1 (29,31,66,67). In the Fab
region, the hinge residues
223CCVECPPCPAPPVAGP238 and the last
Cys residue on the light chain (C-terminus)
were unresolved. In the Fc region, most of
the unresolved residues (235VAGP238,
265DVSHEDPE272, 294EQF296 and
325NKGLP329) were on one of the two heavy
chains, but were resolved in the other heavy
chain. 445PGK447 on both heavy chains at
the C-terminus were also unresolved. The
missing Fc residues were reconstructed by
replacing the entire heavy chain with a
duplicate of the complete heavy chain using
superimposition using PyMOL version 1.3
(Schrödinger, LCC). The root-mean square
difference of the superimposition of the
newly built and original heavy chains of
209 and 190 residues was low at 0.0852 nm,
showing excellent agreement between the
two structures. The missing hinge
223CCVECPPCPAPPVAG237, and the C-
terminal residues for both the light and
heavy chains were modelled with backbone
φ and ψ angles of 10° using the PyMOL 
script build_seq (PyMOL Script
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Repository, Queen’s University, Ontario,
Canada). All disulfide bonds were retained.
Force field parameterizations were
generated and the hydrogen atoms were
added to the starting IgG2 structure using
the glycan reader component of
CHARMM-GUI (68,69) and the
CHARMM36 forcefield (70-74). This
includes the disulfide bond between the
light chain and heavy chain. The starting
structure was then energy minimised for
2000 steps in NAMD (version 2.9) as the
simulation engine (https://sassie-
web.chem.utk.edu/sassie2/).
Dihedral Monte Carlo simulations
Dihedral Monte Carlo simulations
in SASSIE used the Complex Monte Carlo
module whereby 400,000 models were
sampled rapidly (75). This module varied
backbone dihedral angles for the IgG2
hinge residues
220ERKCCVECPPCPAPPVAGP238. A
Metropolis sampling methodology was
used to sample the energetically-allowed
dihedral angles, using only the dihedral
component of the CHARMM potential to
determine the energy of each configuration
(70). Sterically-overlapping IgG structures
were removed during sampling. Overall,
from the total of 400,000 generated IgG2
models, 123,371 models were accepted for
the scattering fits.
The different conformational
searches of IgG2 were as follows:
(i) First, 200,000 simulations were
performed without any disulfide bond
constraints in which the entire hinge
220ERKCCVECPPCPAPPVAGP238 was
varied in the sampling. Maximum rotation
angle steps of 30° were used in this
simulation. From this search, 106,799
models (53%) were sterically acceptable
with no overlaps.
(ii) Using the models from search (i),
four were selected as new starting
structures. These were selected by
measuring the α-carbon distances between 
the hinge residue pairs Cys223-Cys223,
Cys224-Cys224, Cys227-Cys227 and
Cys230-Cys230 to be under 1 nm, these
being the only four models that met this
criterion. A simulation of 20,000 structures
for each of these four starting structures was
performed with the constraint that the four
cysteine pairs involved in inter-heavy chain
disulfide bonding remained within 1 nm of
one another (i.e. “disulfide distance”
constraints). The entire hinge
220ERKCCVECPPCPAPPVAGP238 was
varied in the simulation with maximum
rotation angle steps of 15°. This produced
9,560 accepted structures that retained their
1 nm separation (12%) out of the total of
80,000 simulations.
(iii) Subsequently, a further five starting
structures were defined by setting the α-
carbon distances between the four pairs of
hinge cysteines Cys223-Cys223, Cys224-
Cys224, Cys227-Cys227 and Cys230-
Cys230 to be under 0.75 nm in the best fit
models from the 9,560 structures (as
above). Four of the structures showed no
cross-over at their hinges, meaning that
each Fab region remained on the same side
of the IgG structure as their CH2 and CH3
domains (Figure 1). One of the five
structures showed a slight crossover of its
hinges. The first four starting structures
were subjected to disulfide distance
constraints of 0.75 nm between each of the
four hinge cysteine pairs in a simulation of
80,000 structures, from which 3,108 (4%)
were accepted. The fifth structure was
subjected to constraints of 1 nm α-carbon 
separations between each of the four hinge
cysteine pairs in a simulation of 20,000
structures, of which 3,037 models were
accepted (15%). The entire hinge
220ERKCCVECPPCPAPPVAGP238 was
varied in the sampling with maximum
rotation angle steps of 15° used in all five
simulations.
(iv) As a control, the same starting
structure used for (ii) and (iv) were
subjected to two different filters of either 1
nm or 0.75 nm α-carbon separations in the 
Cys pairs to confirm that the filters in
SASSIE were not biased in producing
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accepted models during the simulation and
that the SASSIE simulation produced
randomised trial models. One of the starting
structures from (ii) was subjected to a
further simulation of 20,000 structures
using a constraint of ≤ 0.75 nm in α-carbon 
separation for each of the four cysteine
pairs in the hinge. The entire hinge
220ERKCCVECPPCPAPPVAGP238 was
varied in the sampling with maximum
rotation angle steps of 15°, and 867 models
from 20,000 were accepted (4%).
Scattering curve calculations and analyses
The scattering curves for the
123,371 accepted models were calculated
using the SCT software package (49). This
is a coarse-grained method that converts the
atomistic models into small sphere models
for use with the Debye equation adapted to
spheres to calculate the theoretical
scattering curves I(Q) (76). For comparison
with neutron data, the sphere models were
left unhydrated, however smearing
corrections were applied (wavelength 0.60
nm; wavelength spread 10%, beam
divergence of 0.016 radians). For
comparison with X-ray data, hydration
spheres were added to create a hydration
shell corresponding to 0.3 g of water per
gram of protein (33,34). The atomic co-
ordinates were converted into small sphere
models using a grid with cube-side length
of 0.54298 nm and a cut-off of four atoms,
and these parameters were optimized using
SCT to reproduce the unhydrated protein
volume. The target dry volume was 189.9
nm3 (the modelled dry volume was 189.9
nm3) and the target wet volume was 250.1
nm3 (the modelled hydrated volume was
253.6 nm3). For comparison with the X-ray
and neutron scattering data, each
experimental I(Q) value was matched to the
theoretical I(Q) value with the closest Q
value, after which the R-factor was
computed by analogy with crystallography
where lower R-factors represent better fits:
η is a scaling factor used to match the 
theoretical curve to the experimental I(0)
value. An iterative search to minimize the
R-factor was used to determine η. The 
theoretical scattering curves that matched
the experiment scattering curves were
accepted as valid models of the antibody
solution structure. The experimental curves
were fitted using a Q-range of 0.13 – 2 nm-
1 for the X-ray and neutron curves.
A cut-off R-factor, below which
models were assigned as best-fit, depended
on the experimental scattering curve, its
signal-to-noise ratio and its Q range. To
determine this cut-off, two experimental
curves were used to calculate two R-factors
for each of the 123,371 curves. The
correlation between the two R-factors was
assessed using both the Pearson r and
Spearman rs coefficients (77). By gradually
excluding the models with higher R-factors,
this identified the point at which the ranking
of the fits was no longer consistently
determined for the two curves. The cut off
was chosen as the point where both the r
and rs coefficients dropped below 0.5 (31).
If there is a correlation between the two
compared curves where r and rs is not equal
to 0.5, then the cut-off R-factor filter
selected is the minimum R-factor for that
experimental curve plus 1-2 %. Here, the
number of accepted models was reduced by
approximately two-thirds using the R-factor
cut-off filter to select for the better models
with a lower R-factor. To analyse the
models, the distance between the centres of
mass of the two Fab region (d1), and the
distances between the centres of mass of
each Fab region to the Fc region (d2 and d3)
were measured (Figure 1). Note that since
IgG2 is symmetric, thus the differentiation
between Fab1 and Fab2 and the
corresponding d2 and d3 values is for
clarity. The Fab1 and Fab2 structures in the
18
models were distinguished according to
their chain names. The asymmetry of an
antibody structure was measured by the
absolute difference between the two Fab-Fc
distances, abs(d2-d3).
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Table 1. Experimental X-ray and neutron scattering data and sedimentation coefficients for human myeloma IgG2
Sample Rg (nm)a Rxs-1 (nm) Rxs-2 (nm) Dmax (nm) s020,w (S)
X-ray scattering
0.5 mg/ml, PBS-50 5.24; 5.40 2.61 1.35 18 7.44b
1.0 mg/ml, PBS-137 5.23; 5.36 2.61 1.37 18 7.32
1.5 mg/ml, PBS-250 5.38; 5.52 2.61 1.37 18 7.26b
Neutron scattering
0.45 mg/ml, PBS-50 in 100% 2H2O 5.04; 5.20 2.39 1.12 17 7.24b
1.0 mg/ml, PBS-137 in 100% 2H2O 4.97; 5.00 2.45 1.15 17 7.28
1.99 mg/ml, PBS-250 in 100% 2H2O 4.95; 5.03 2.39 1.12 17 6.96b
a The first experimental value was from the Guinier Rg analysis (Figure 8), and the second one was from the GNOM P(r) analysis (Figure 9).
b The sedimentation coefficients s020,w were for IgG2 at 0.54, 1.55, 0.90 and 0.64 mg/ml respectively, and not as in column 1.
n.a. not available.
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Table 2. Modelling of the X-ray (upper) and neutron (lower) scattering data for human myeloma IgG2





All IgG2 models None 123,371 3.85-6.21 1.34-3.36 0.02-2.30 n.a. 3.48-13.97 3.33-9.70 4.55-10.34
X-ray fit, 0.5 mg/ml,
PBS-50 R-factor ≤ 5.5% 35,141 4.83-5.45 2.23-2.96 0.71-1.78 4.04-5.50 4.95-12.70 4.91-9.66 6.27-10.21 
R-factor ≤ 5.5% 
and 4 disulfides 1,474 4.83-5.04 2.56-2.79 1.26-1.51 4.61-5.50 5.55-7.54 6.80-8.39 7.62-8.92
X-ray fit, 1 mg/ml,
PBS-137 R-factor ≤ 5% 30,088 4.84-5.45 2.23-2.94 0.71-1.78 3.53-5.00 4.95-12.70 4.91-9.66 6.27-10.21 
R-factor ≤ 5% and 
4 disulfides 1,247 4.84-5.04 2.56-2.79 1.26-1.51 4.15-5.00 5.55-7.54 7.15-8.39 7.62-8.92
X-ray fit, 1.5 mg/ml,
PBS-250 R-factor ≤ 5.7% 42,292 4.85-5.52 2.23-3.01 0.61-1.82 3.62-5.70 4.90-12.86 4.91-9.69 6.19-10.23 
R-factor ≤ 5.7% 
and 4 disulfides 1,100 4.86-5.04 2.56-2.79 1.26-1.51 4.72-5.70 5.55-7.54 6.97-8.39 7.65-8.92




R-factor ≤ 6% 44,835 4.75-5.39 2.03-2.79 0.64-1.56 4.15-6.00 5.21-13.87 5.17-9.70 6.53-10.23 
R-factor ≤ 6% and 




R-factor ≤ 3.75% 10,731 4.75-5.22 2.16-2.65 0.87-1.48 2.85-3.75 5.69-13.39 5.51-9.70 6.65-10.23 
R-factor ≤ 3.75% 




R-factor ≤ 8.2% 35,213 4.70-5.48 1.92-2.75 0.06-1.62 6.13-8.20 5.16-13.97 4.99-9.70 6.53-10.23 
R-factor ≤ 8.2% 








N: 1.28-1.32 n.a. 6.84-7.14 7.81-8.01 8.00-8.39
a Models that satisfy the R-factor and disulfide filters and the Rg, Rxs-1 and Rxs-2 parameters for both X-rays (X) and neutrons (N) are displayed.




The human IgG2 domain structure. The two heavy chains each possess VH, CH1, CH2 and
CH3 domains, and the two light chains each possess VL and CL domains. The heavy chains are
connected by four Cys–Cys disulfide bridges at Cys223, Cys224, Cys227 and Cys230. There
is one N-linked oligosaccharide site at Asn297 on each of the CH2 domains. The hinge region
between the Fab and Fc fragments is composed of 19 residues (ERKCCVECPPCPAPPVAGP)
between Val219 and Ser239 (EU numbering). Below the black diagram, the distance between
the centres of mass of the two Fab regions (blue, yellow) was denoted as d1. Those between
the two Fab and Fc regions were denoted as d2 and d3. The antibody is shown as a two-fold
symmetric structure with d2 = d3. In general, d2 and d3 are unequal. In the text, the smaller of
the two values is denoted as min(d2,d3) and the larger of the two is denoted as max(d2,d3).
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FIGURE 2
Sequence alignment of IgG2 with human IgG1 6a and IgG1 19a and IgG4. The IgG2 sequence was taken from IgG2 Li33 (13). The IgG1
6a and 19a sequences were taken from (27). (A, B) The VL, and CL domains. (C-E) The VH and CH1 domain and the hinge. (F,G) The CH2 and
CH3 domains. (H) Comparison of hinge sequences from human IgG1, IgG2 and IgG4 subclasses. In E-F, yellow indicates the contact residues
involved in the IgG1-Fc complex with the C1q globular head, blue indicates the contact residues required for interacting with FcγRI, and green 
indicates the contact residues that interact with both C1q and FcγRI.
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FIGURE 3
Purification of IgG2. The IgG2 elution peak from a Superose 6 10/300 gel filtration column
is shown on the left (mAU, milli-absorbance units). The non-reduced and reduced SDS-PAGE
analysis of the IgG subclasses is shown on the right with H2L2 representing the intact antibody
molecule, H the heavy chain and L the light chain. Lane 1 and 10 contain Mark 12 molecular
weight markers labelled in kDa. Lanes 2-3, 4-5, 6-7 and 8-9 contain non-reduced and reduced
IgG2, non-reduced and reduced IgG1 6a, non-reduced and reduced IgG1 19a and non-reduced
and reduced IgG4 B72.3 respectively.
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FIGURE 4
Native mass spectrometry of glycosylated and deglycosylated IgG2. Native mass spectra of
myeloma IgG2 are shown at a mass-to-charge ratio (m/z) between 5,000-7,500. The
glycosylated and deglycosylated IgG2 mass spectra are shown in (A) and (B) respectively. The
theoretical charge states were generated using Amphitrite software and labelled.
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FIGURE 5 Sedimentation velocity analyses of IgG2. The experimentally observed
sedimentation boundaries for IgG2 in the left panels in (A) PBS-50, (B) PBS-137, (C) PBS-250
in H2O buffers and in (D) PBS-50, (E) PBS-137 and (F) PBS-250 in 100% 2H2O buffers were
recorded at a rotor speed of 40,000 r.p.m and 20°C. Approximately fifty boundaries (black
outlines) are shown from up to 300 scans for every sixth scan for clarity, and were fitted using
SEDFIT as shown (white lines). In the right panels, the corresponding size-distribution
analyses c(s) are shown to reveal a major monomer (M) peak and a minor dimer (D) peak. The
observed c(s) peaks are shifted to lower s values in 2H2O buffers.
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FIGURE 6
Sedimentation coefficient values and amounts of IgG2. (A) The s20,w values for the monomer
and dimer peaks are shown as a function of IgG2 concentration in the six buffers of this study.
(B) The percentages of monomer and dimer from the c(s) integrations. IgG2 is shown in PBS-
50 (), PBS-137 (), PBS-250 () buffers in H2O at 20°C and in PBS-50 [], PBS-137 []
and PBS-250 [] buffers at 20°C in 100% 2H2O. The average s20,w values of monomer and
dimer from the integration of the c(s) analyses for IgG2 are shown for H2O (- -) and 2H2O (―) 
buffers at 20°C.
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FIGURE 7 X-ray and neutron Guinier Rg and Rxs analyses for IgG2.
The X-ray scattering curves of IgG2 are shown for three buffers: (A) PBS-50, (B) PBS-137
and (C) PBS-250 at 20 °C. The concentrations were approximately 0.5, 1.0 and 1.5 mg/ml for
PBS-50 and PBS-137 and 1.0 and 1.5 mg/ml for PBS-250 from bottom to top. The filled circles
between the arrowed data points represent the Q.Rg and Q.Rxs ranges used to determine the Rg
and Rxs values. The Q-ranges used for the Rg, Rxs-1 and Rxs-2 values were 0.15-0.28 nm-1, 0.31-
0.47 nm-1 and 0.65-1.04 nm-1 respectively.
The neutron scattering curves of IgG2 are shown for three buffers: (D) PBS-50, (E) PBS-137
and (F) PBS-250 at 20 °C in 100% heavy water. The concentrations were approximately 0.30,
0.59, 1.19 and 2.38 mg/ml for PBS-50, 0.5, 1.0, 2.0 and 3.0 mg/ml for PBS-137 and 0.33, 1.99
and 2.66 mg/ml for PBS-250 from bottom to top. The filled circles between the arrowed data
points represent the Q.Rg and Q.Rxs ranges used to determine the Rg and Rxs values. The Q-
ranges used for the Rg, Rxs-1 and Rxs-2 values were 0.15-0.28 nm-1, 0.31-0.47 nm-1 and 0.65-1.04




Concentration dependence of the X-ray and neutron Guinier parameters for IgG2. The
Rg, Rxs-1 and Rxs-2 values are displayed from top to bottom for each buffer. (A) The X-ray
Guinier values for IgG2 are shown for PBS-50 [], PBS-137 [] and PBS-250 [] buffers at
20°C. The P(r) Rg values are shown for PBS-50 [], PBS-137 [] and PBS-250 [] at 20°C.
(B) The neutron Guinier values for IgG2 are shown for PBS-50 [], PBS-137 [] and PBS-
250 [] buffers at 20°C in 100% heavy water. The P(r) Rg values are shown for PBS-50 [],
PBS-137 [] and PBS-250 [] at 20°C in 100% heavy water.
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FIGURE 9 X-ray and neutron distance distribution analyses P(r) for IgG2. The peak
maxima M1 and M2 and maximum length at L are indicated by arrows.
(A) The X-ray P(r) curves for IgG2 in PBS-50, PBS-137 and PBS-250 (H2O) are shown for
concentrations at approximately 0.5, 1.0 and 1.5 mg/ml for PBS-50 and PBS-137 and 1.0 and
1.5 mg/ml for PBS-250 from bottom to top.
(B) The neutron P(r) curves for IgG2 in PBS-50, PBS-137 and PBS-250 at 20 °C in 100%
heavy water. Concentrations were approximately 0.30, 0.45, 0.59, 1.19 and 2.38 mg/ml for
PBS-50, 0.5, 1.0, 2.0, 3.0 and 4.0 mg/ml for PBS-137 and 0.33, 1.99 and 2.66 mg/ml for PBS-
250 from bottom to top.
(C) The X-ray M1 and M2 values are shown for PBS-50 (), PBS-137 () and PBS-250 ()
buffers.
(D) The neutron M1 and M2 values are shown for PBS-50 (), PBS-137 () and PBS-250
() in 100% heavy water buffer. The lines are the mean values for M1 (―) and M2 (- -). 
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FIGURE 10
Modelling analyses for IgG2. The 123,371 goodness-of-fit R-factors were compared with the
X-ray and neutron Rg values calculated for the IgG2 models. All 123,371 models are shown in
grey. The 5,242 models filtered using a separation of 0.75 nm for each of the four pairs of
cysteine residues in the hinge (Figure 1) are shown in blue circles. The 13 best-fit models that
were accepted for each X-ray and neutron pair according to three filters (X-ray and neutron R-
factor cut-offs and disulfide separations) are shown in yellow circles and arrowed. The
experimentally observed Guinier Rg values are shown by vertical solid lines with error ranges
of ± 5% shown by dashed lines. (A) The hydrated X-ray models were compared with the
experimental X-ray curve of 0.5 mg/ml IgG2 in PBS-50 where the orange circles shows 35,141
models with a R-factor below 5.5%. (B) The hydrated X-ray models were compared with
experimental X-ray curve of 1 mg/ml IgG2 in PBS-137 where the orange circles shows 30,088
models with a R-factor below 5%. (C) The unhydrated neutron models were compared with
experimental neutron curve of 0.45 mg/ml IgG2 in PBS-50 in 100% 2H2O where the red circles
shows 44,835 models with a R-factor below 6%. (D) The unhydrated neutron models were
compared with experimental neutron curve of 1 mg/ml IgG2 in PBS-137 in 100% 2H2O where
the red circles shows 10,731 models with a R-factor below 3.75%.
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FIGURE 11
Density plots of the best-fit IgG2 models in PBS-137 buffer. The graphics were rendered
using Tachyon in VMD.
(A) The density plot for all 123,371 models is shown as a mesh with the Fc region shown as a
grey solid surface. This is the reference for (B-F).
(B) Models that satisfied a X-ray R-factor cut-off below 5% for the curve at 1 mg/ml in PBS-
137 in 100% light water. The two Fab regions are shown in gold and orange (30,088 models).
(C) Models that satisfied a neutron R-factor cut-off of 3.75% for the curve at 1 mg/ml in PBS-
137 in 100% heavy water. The two Fab regions are shown in red and purple (10,731 models).
(D) Models that satisfied both the X-ray and neutron R-factors. The two Fab regions are shown
in brown and tan (4,866 models).
(E) Models that satisfied a separation of 0.75 nm between each of the four pairs of cysteine
residues in the IgG2 hinge. The two Fab regions are shown in cyan and blue (5,242 models).
(F) The 13 final best-fit models for IgG2 in PBS-137 that meet the X-ray and neutron R-factor
cut-off and disulfide filters. The two Fab regions are shown in purple and black (13 models).
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FIGURE 12
X-ray and neutron scattering curve fits and Kratky analyses for the best-fit IgG2 models.
The experimental data are indicated by white open circles and the modelled best-fit curve is
indicated in red. The models show 0.75 nm separations between each of the four pairs of
cysteines in the IgG2 hinge. The X-ray best fits correspond to (A) 0.5 mg/ml of IgG2 in PBS-
50, (B) 1 mg/ml of IgG2 in PBS-137, (C) 1.5 mg/ml of IgG2 in PBS-250. The neutron best fits
correspond to and (D) 0.45 mg/ml of IgG2 in PBS-50, (E) 1 mg/ml of IgG2 in PBS-137 and
(F) 1.99 mg/ml of IgG2 in PBS-250 in 100% 2H2O. The insets correspond to the experimental
(black) and best-fit modelled (red) P(r) curves, in which M1, M2 and L are arrowed. (G-L) The
corresponding Kratky plots for the same six comparisons between experiment and models are
shown.
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FIGURE 13 Distribution of the Fab-Fab and Fab-Fc distances in human IgG2.
The analyses are shown for 1 mg/ml of IgG2 in PBS-137. The inter-Fab distance, d1 between
the centre-of-mass of the two Fab arms and the absolute difference in Fab to Fc distances, d2-
d3 are shown (Figure 1).
(A) All 123,731 models from the Monte Carlo simulations are shown in grey. The 30,088
models with an X-ray R-factor below 5% are shown in orange. The 10,731 models with a
neutron R-factor below 3.75% are shown in red. The 4,866 models filtered by both the X-ray
and neutron R-factor filters are shown in brown. The 5,242 models that have less than 0.75 nm
separations for each of the four pairs of cysteine residues in the hinge are shown in blue. The
13 best-fit models that satisfy the X-ray and neutron and disulfide filters are shown in black.
(B) The IgG2 models (black) denote those that meet the X-ray and neutron and disulfide filters
from (A), and are compared with those for IgG1 (red) and IgG4 (blue) that were calculated in
the same way.
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FIGURE 14 Superimposition of the nine IgG2 best-fit models with complement
C1q and two Fc receptors. The nine IgG2 best-fit models are compared with crystal structures
for the IgG1-C1q, IgG1- FcγRI and IgG1- FcγRIII complexes. Superimpositions of the Fc 
regions of the IgG2 models with the crystal structures of the Fc complexes were achieved using
the “align” function of PyMol. The IgG2 Fab regions are shown in blue (Fab1) and yellow
(Fab2) and the Fc region in dark grey as in Figure 1. The Fc region is seen in the same view in
A, B and C (left), and is rotated by 90º in C (right). The glycans in the IgG2 Fc region are
represented as sticks and the IgG2 hinge is represented as red loops.
(A) Superimposition of the nine IgG2 best-fit models with the IgG1-Fc complex with the
globular head of C1q (PDB code 6FCZ). The IgG1-Fc region is represented as a light grey
cartoon, and C1q is represented as a cyan semi-transparent surface.
(B) Superimposition of the nine IgG2 best-fit models with the IgG1-Fc complex with FcγRI 
(PDB code 4X4M). The IgG1-Fc region is represented as a light grey cartoon and FcγRI is 
represented as a cyan semi-transparent surface.
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(C) Two orthogonal views at 90° of the superimposition of the IgG2 best-fit model with three
crystal structures for the IgG1-Fc complexes with FcγRIIIA V158 (PDB codes 3SGJ, 5VU0 
and 5YC5). The IgG1-Fc regions are represented as light grey cartoon schematics and
FcγRIIIA are represented as cyan cartoons.
